Form 8-K - Current report:
SEC Accession No. 0001193125-25-037588
Filing Date
2025-02-27
Accepted
2025-02-27 07:13:07
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d922874d8k.htm   iXBRL 8-K 26710
2 EX-99.1 d922874dex991.htm EX-99.1 65474
6 GRAPHIC g922874g0227005718190.jpg GRAPHIC 3519
  Complete submission text file 0001193125-25-037588.txt   231324

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250227.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250227_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250227_pre.xml EX-101.PRE 11263
17 EXTRACTED XBRL INSTANCE DOCUMENT d922874d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 25672977
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)